Fractional CO₂ Laser for Primary Cutaneous Amyloidosis
NCT: NCT07815132 · COMPLETED
Brief Summary
This randomized, controlled clinical study will evaluate the clinical and ultrastructural effects, efficacy, and safety of fractional CO₂ laser in patients with primary cutaneous amyloidosis. Twenty-two eligible patients will be randomly allocated in a 1:1 ratio to receive either three fractional CO₂ laser sessions at 4-week intervals or no active laser treatment (control group). The primary outcome will be the change in the Amyloidosis Severity Score from baseline to one month after the final laser session, with secondary assessments including dermoscopic findings, transmission electron microscopy findings, pruritus severity, patient satisfaction, and adverse events.
Frequently Asked Questions
What is Fractional CO₂ Laser for Primary Cutaneous Amyloidosis?
Fractional CO₂ Laser for Primary Cutaneous Amyloidosis is a clinical trial registered under NCT07815132. Current status: COMPLETED.
What is the status of NCT07815132?
The current status of NCT07815132 (Fractional CO₂ Laser for Primary Cutaneous Amyloidosis) is: COMPLETED.
When did Fractional CO₂ Laser for Primary Cutaneous Amyloidosis start?
Fractional CO₂ Laser for Primary Cutaneous Amyloidosis started on 2024-09-10.
Related Devices
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.